A BMP/activin A chimera is superior to native BMPs and induces bone repair in nonhuman primates when delivered in a composite matrix
Howard Seeherman(BioVentures (United States)), Stephen P. Berasi(Pfizer (United States)), Christopher Brown(BioVentures (United States)), Robert Martinez(Pfizer (United States)), Z. Sean Juo(Pfizer (United States)), Scott A. Jelinsky(Pfizer (United States)), Michael Cain(Pfizer (United States)), Jaclyn Grode(BioVentures (United States)), Kathleen E. Tumelty(Pfizer (United States)), Marc Bohner(RMS Foundation), Orly Grinberg(Israel Institute for Biological Research), Nadav Orr(Israel Institute for Biological Research), Oded Shoseyov(Israel Institute for Biological Research), Jeroen Eyckmans(Boston University), Christopher S. Chen(Boston University), Pablo Morales(Technische Hochschule Mannheim), Christopher G. Wilson(BioVentures (United States)), Eric J. Vanderploeg(BioVentures (United States)), John M. Wozney(BioVentures (United States))
Cited by 66
Abstract
of the BMP-2/absorbable collagen sponge (ACS) concentration approved for clinical use. Initial toxicology studies were negative. These results support evaluations of BV-265/CM as an alternative to BMP-2/ACS in clinical trials for orthopedic conditions requiring augmented healing.